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SUMMARY
Treatment with indinavir has been shown to result in marked decreases in viral load and increases in CD4 cell counts in HIV-
infected individuals. A randomized double-blind study to evaluate the efficacy of indinavir alone (800 mg q8h), zidovidine alone (200
mg q8h) or the combination was performed to evaluate progression to AIDS. 996 antiretroviral therapy-naive patients with CD4 cell
counts of 50-250/mm3 were allocated to treatment. During the trial the protocol was amended to add lamivudine to the zidovudine-
containing arms. The primary endpoint was time to development of an AIDS-defining illness or death. The study was terminated after
a protocol-defined interim analysis demonstrated highly significant reductions in progression to a clinical event in the indinavir-
containing arms, compared to the zidovudine arm (p<0.0001). Over a median follow-up of 52 weeks (up to 99 weeks), percent
reductions in hazards for the indinavir plus zidovudine and indinavir groups compared to the zidovudine group were 70% and 61%,
respectively. Significant reductions in HIV RNA and increases in CD4 cell counts were also seen in the indinavir-containing groups
compared to the zidovudine group. Improvement in both CD4 cell count and HIV RNA were associated with reduced risk of disease
progression. All three regimens were generally well tolerated.
KEYWORDS: Randomized study; Double blind clinical trial; HIV; AIDS; Protease inhibitors; Indinavir; Zidovudine; Disease
progression; Therapy; Clinical endpoint.
INTRODUCTION
The introduction of protease inhibitors for the therapy of human
immunodeficiency virus type 1 (HIV-1) infection has been associated
with a marked decrease in morbidity and mortality in HIV-1 infected
individuals2,14,25,27. Early studies demonstrated that monotherapy with
certain protease inhibitors resulted in marked decreases in HIV RNA
and increases in CD4 cell counts6,12,18,31. Subsequently, the use of the
protease inhibitor indinavir in combination with zidovudine plus
lamivudine was shown to have superior antiretroviral efficacy compared
to zidovudine plus lamivudine in several clinical trials12,14. In a study of
zidovudine experienced patients with 50-400 CD4 cells/mm3, the triple
combination of indinavir plus zidovudine plus lamivudine suppressed
HIV RNA to below 500 copies/mL in more than 80% of patients12.
Recently, therapy with indinavir in combination with zidovudine plus
lamivudine was shown to reduce the rate of clinical HIV-1 disease
compared to zidovudine plus lamivudine in zidovudine experienced
patients with £200 CD4 cells/mm3 14.
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In this study, we compared the clinical efficacy, antiretroviral activity
and safety of indinavir to zidovudine or the combination of indinavir
plus zidovudine in HIV-1 infected patients who were antiretroviral
therapy-naive with CD4 cell counts between 50 and 250 cells/mm3. The
study began in April 1995; and at that time, zidovudine monotherapy
was the standard of care for antiretroviral therapy-naive patients. As
data from other trials became available indicating the superiority of double
nucleoside analogue combinations over zidovudine monotherapy7,13,28,
the study was amended to add lamivudine to the regimens of patients in
either zidovudine containing arm.
 The study was conducted entirely in Brazil and represents the first
large clinical endpoint trial in HIV-infected patients performed in a
developing country. Patients were recruited at four large STD/AIDS
clinics in São Paulo, and one in Campinas. From 1980 to 1996, of the
82,852 cases of AIDS reported in Brazil, 55% were reported in this
region of the country29. Protease inhibitors were initially licensed in Brazil
in January 1996, and were widely distributed to patients by the Brazilian
Ministry of Health by November 1996.
METHODS
Patient population
Antiretroviral therapy-naive, HIV-1 seropositive, male or female
patients at least 18 years old with a prestudy CD4 cell count of 50-250
cells/mm3 (average of two determinations) were eligible for enrollment.
Patients were required to meet a list of prestudy laboratory requirements
(hematology, chemistry, coagulation) and to be free of any conditions
consistent with the early stages of an opportunistic infection (OI). Major
exclusion criteria were: use of chronic therapy for an active opportunistic
infection or malignancy; history of OI, and use any other investigational,
immunomodulatory or immunosuppressive agents. The protocol was
approved by the Brazilian Ministry of Health, and by the ethical review
committees of the participating institutions. Each patient provided written
informed consent.
Study Design and Endpoints
The study was designed to compare the efficacy and safety of
indinavir alone (800 mg q8h) to zidovudine alone (200 mg q8h) or to
the combination of both. Patients were stratified according to prestudy
CD4 cell count (Stratum I: 50-150 cells/mm3; Stratum II: 151-250 cells/
mm3) and randomly allocated in a 1:1:1 ratio to one of the three
treatment groups. The study was conducted in a double-blind fashion,
including sponsor blinding, and enrolled 996 patients beginning in
April 1995.
The primary objective of the study was to compare the efficacy of
the three treatment regimens as measured by time to progression to first
clinical event (AIDS-defining illness or death). Clinical events and
corresponding diagnostic criteria were specified per protocol and based
on the 1993 CDC case definition4. Histological/microbiological diagnoses
were required for most events, but presumptive diagnoses of CMV
retinitis, progressive multifocal leukoencephalopathy, and toxoplasmosis
of the brain, based on pre-defined criteria, were also accepted. Additional
objectives of the study were to compare the three treatment regimens
with respect to safety (clinical adverse events, laboratory abnormalities),
and changes in surrogate markers (CD4 cell counts, HIV RNA).
Laboratory safety tests, CD4 cell counts, and HIV RNA measurements
were performed by central laboratories. The Amplicor HIV-1 Monitor
assay (Roche Diagnostics, NJ, USA) was used to measure the level of
HIV RNA in serum.
In July 1996 the protocol was amended to modify the zidovudine-
containing treatment groups as data from other trials became available
demonstrating the superiority of certain double nucleoside analogue
combinations over zidovudine monotherapy7,13. In a blinded manner,
patients who had not yet experienced a clinical event were offered the
option of receiving lamivudine (150 mg, b.i.d.) or placebo in addition to
other protocol therapy. Of the 817 eligible patients, 783 (96%) elected
to add lamivudine or placebo. Patients who were originally randomized
to a zidovudine-containing regimen (zidovudine alone, or indinavir plus
zidovudine) added lamivudine, while patients randomized to indinavir
monotherapy added lamivudine placebo. Although the treatment groups
were modified, treatment allocation remained blinded. All analyses were
done according to the original treatment group assignments, as the study
was not designed to definitively answer questions regarding the addition
of lamivudine. The median study week for addition of lamivudine or
placebo was Week 41.
The study was designed with 95% power to detect a 30% reduction
in clinical events (AIDS-defining illness or death), assuming a rate of
20% per year for such events in the zidovudine arm. The design was
event-based with a fixed sample size and study completion when 300
patients had each experienced at least one confirmed clinical event. To
control for increased probabilities of Type I error due to multiple interim
analyses, an alpha spending function8 was employed to maintain a
conservative Type I error at early analyses, to preserve the overall Type
I error close to a=0.025, and to allow interim assessment at irregular
intervals. This alpha spending rate function approximates the boundaries
of O’BRIEN & FLEMING23. A critical overall a=0.025 was employed
to protect against increased chances of Type I error as there were two
pairwise comparisons of the indinavir containing arms versus zidovudine.
Patient Follow-Up
Patients reported for scheduled visits at Weeks 2 and 4, every 4 weeks
thereafter, upon discontinuation, and 2 weeks following discontinuation.
At each visit, patients underwent a physical examination, and aggressive
surveillance for clinical events and other adverse experiences. Laboratory
safety testing, CD4 cell counts, and HIV RNA measurements were
performed at frequent intervals. Investigators and patients had access to
all of their test results except HIV RNA measurements. Toxicity
management guidelines were defined per protocol for isolated
hyperbilirubinemia, granulocytopenia, anemia, nausea, vomiting, and
renal colic.
Blinded documentation (laboratory reports, narrative summary) of
all protocol-defined clinical events was promptly forwarded to an
independent Data and Safety Monitoring Board (DSMB) responsible
for final confirmation of each diagnosis as a clinical event. Upon
confirmation of the clinical event, patients were offered the option to
permanently discontinue all blinded study therapy, and begin therapy
with open-label indinavir, alone or in combination with one or more
nucleoside analogues. Patients with presumptive diagnoses of
Pneumocystis carinii pneumonia, Mycobacterium tuberculosis or other
diagnoses considered to reflect treatment failure but not defined as clinical
events per protocol were offered the option to continue on blinded
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indinavir or placebo, plus open-label nucleoside analogue therapy. The
protocol allowed a double-blind treatment duration of up to 156 weeks,
but included provisions for changes in study design based on planned
interim analyses performed at time points determined by the number of
clinical events observed, or at the discretion of the DSMB. Charged
with the responsibility to periodically review enrollment and safety and
efficacy data, the DSMB in March 1997 recommended that the double-
blind portion of the study be ended due to the superior clinical efficacy
of the indinavir-containing groups over the zidovudine group. The
protocol was amended to provide all patients with open-label indinavir,
and the study is ongoing for long-term follow-up purposes.
Statistical Methods
Analyses of all efficacy variables were performed on the intention
to treat basis that included all patients randomized and all available
follow-up (including that obtained after discontinuation of study
treatment). Statistical models included the randomization blocking factors
of investigative sites and screening CD4 cell count strata as main effects.
Nominal two-sided p-values are reported. Estimates of treatment
differences and 95 percent confidence intervals are unadjusted for
multiplicity.
The distributions of times to clinical events were compared between
treatment groups by Kaplan-Meier estimates, stratified log rank tests
and Cox proportional hazards models. Patients who did not progress to
the primary endpoint had time to event censored at the date of last follow-
up.
The primary metric for analysis of surrogate marker changes from
baseline was the area under the curve minus baseline (AUCMB)19. The
AUCMB estimated the average change from baseline over the time of
follow-up, using all observed data. With respect to HIV RNA, values
below assay detection were set equal to 250 copies/mL and detectable
values below the assay threshold of quantification (500 copies/mL) were
set equal to 500 copies/mL. For the presentations of changes from baseline
in HIV RNA and CD4 cell count, data for patients who discontinued
from the study or experienced a clinical event were censored at the time
of the discontinuation or clinical event, respectively.
Proportions of patients whose HIV RNA levels were below the assay
threshold of quantification (500 copies/mL) were determined. This
analysis accounts for the virological status of all patients enrolled,
including those who were lost to follow-up. All patients who discontinued
from the study or experienced a clinical event, and who had HIV RNA
levels of at least 500 copies/mL at the time of discontinuation or the
clinical event, were considered to be failures at subsequent time points.
Patients who discontinued the study due to a drug-related adverse
experience were considered to have HIV RNA levels greater than or
equal to 500 copies/mL at time points subsequent to their discontinuation,
regardless of viral burden at the time of the adverse experience. Patients
who discontinued for other reasons (e.g. contraindicated medications,
patient request) or who experienced a clinical event, and who had HIV
RNA levels less than 500 copies/mL at the time of discontinuation or
clinical event, were not included in the analysis of subsequent time points.
When a HIV RNA level was missing at a given time point while the
patient was still being followed, if the HIV RNA levels immediately
preceding and immediately following the missing value were both
measured to be less than 500 copies/mL, the missing value was assumed
to be less than 500 copies/mL; otherwise the missing value was assumed
to be at least 500 copies/mL. In this analysis, the denominator at any
given time point may be comprised both of patients with actual viral
load determinations and of patients with imputed values; in this setting,
the denominator is referred to as “contributing patients”. Exact binomial
95% confidence intervals were calculated based on the proportion of
contributing patients with HIV RNA below 500 copies/mL.
Associations between the surrogate marker results and risk of clinical
progression were examined using the subset of patients with data for
both surrogate markers at study entry and at least one post-randomization
result. Four groups were defined by quartiles of the combined surrogate
marker AUCMB results: low CD4/high HIV RNA, low CD4/low HIV
RNA, high CD4/high HIV RNA, high CD4/low HIV RNA. Estimates
of time to first clinical event were compared graphically between these
quartiles. The quartiles were divided about the level of no net change
from baseline.
Safety was evaluated by tabulation of adverse experiences and
treatment-emergent laboratory abnormalities. All adverse experiences
reported for patients while on study therapy or within 14 days after
discontinuing study therapy were included in the safety analysis. The
proportions of patients in each treatment group experiencing a particular
adverse experience or laboratory abnormality were compared by the
Fisher’s exact test.
RESULTS
Accrual and Baseline Characteristics
996 patients were enrolled in the study between April 1995 and
October 1996. Baseline characteristics for all patients by treatment group
are presented in Table 1. The majority of the patients were male (72%).
Two hundred eighty women (28%) were enrolled into the study. The
median age of all patients was 33 years, ranged from 18 to 67 years of
age at study entry and were Caucasian (88%), in majority. The patients
were approximately evenly split between the two CD4 cell count strata,
with 46% of the patients in the 50 to 150 cells/mm3 stratum. The median
CD4 cell count over all patients was 147.0 cells/mm3. The overall baseline
median viral serum viral RNA was 4.49 log10 copies/mL (30,651 copies/
mL). The indinavir monotherapy group had a lower HIV RNA at baseline
than the other two treatment groups.
Interim analyses; Termination of Double-Blind Period
The study design was based on the assumption that accrual of at
least one clinical event in each of 300 patients would be necessary to
demonstrate a statistically significant difference between the treatment
groups. At the time of the analyses which resulted in the DSMB
recommendation to end the double-blind portion of the study, 107 patients
had experienced at least one clinical event (approximately 36% of the
originally projected 300 clinical events). The critical p-value associated
with 100 events was a two-tailed a = 0.0009 and provided a conservative
stopping guideline.
Patient Accounting and Follow-up
Overall, a total of 165 (17%) patients discontinued their participation
in the study: 66 (20%) in the indinavir plus zidovudine group, 42 (13%)
in the indinavir group and 57 (17%) in the zidovudine group. Only 9
(0.9%) patients discontinued due to a clinical or laboratory adverse
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experience. A total of 25 patients, including 12 patients who died,
discontinued from the study after experiencing a clinical event. Four
patients discontinued the study at the time of a clinical event.
Since the primary objective of this study was to assess clinical
efficacy based on the occurrence of clinical events, the patients who
discontinued from the study without experiencing a clinical event are
especially important as such discontinuations could potentially impact
the results of the primary efficacy analyses. Among the 136 patients
who discontinued without experiencing a clinical event, the difference
in time to discontinuation between the indinavir plus zidovudine group
(57/332, 17%) and the indinavir treatment group (36/332, 11%) was
statistically significant (p=0.0175, log rank test, stratified by
investigative site and screening CD4 cell strata). The differences
between the indinavir plus zidovudine and zidovudine (43/332, 13%)
treatment groups (p=0.1434, stratified log rank test) and the indinavir
versus zidovudine (p=0.3497, stratified log rank test) were not
statistically significant. The follow-up time for clinical progression
ranged from 0 to 99 weeks, with a median follow-up time of 52 weeks
and was similar for all three treatment groups.
Progression to Clinical Event (AIDS-Defining Illness or Death)
One hundred and twelve patients (11%) experienced a clinical event
(AIDS-defining illness or death). Six patients had two different events
with the same diagnosis dates; therefore, there were a total of 118 primary
clinical events. Twenty patients (6%, or 6.8 events per 100 patient-years)
in the indinavir plus zidovudine group had at least one clinical event,
compared to 28 patients (8%, or 8.5 events per 100 patient-years) in the
indinavir group and 63 patients (19%, or 20.8 events per 100 patient-
years) in the zidovudine group. The most common first clinical events
were esophageal candidiasis (42 events), Pneumocystis carinii pneumonia
(12 events), death due to any cause (12 events), and toxoplasmosis of
the brain (10 events).
Kaplan-Meier estimates of progression-free survival by treatment
group are shown in Figure 1. The comparison of indinavir plus zidovudine
to zidovudine was statistically significant (p<0.0001, stratified log rank
test) with an estimated hazard ratio of 0.30 (95% confidence interval:
0.18, 0.50). The comparison of indinavir to zidovudine was also
statistically significant (p<0.0001, stratified log rank test) with an
estimated hazard ratio of 0.39 (95% confidence interval: 0.24, 0.61).
Table 1
Patient characteristics at baseline by treatment group
Demographic characteristics Indinavir plus zidovudine Indinavir Zidovudine Total
(N=332) (N=332) (N=332) (N=996)
Gender - no. (%)
Male 242 (73) 238 (71) 239 (72) 719 (72)
Female  90 (27)  94 (29)  93 (28) 277 (28)
Median age at study entry
(Q1-Q3; years) 33 (29, 40) 33 (29, 39) 33 (29, 40) 33 (29, 39)
Racial origin – no. (%)
Caucasian* 297 (89) 288 (87) 290 (87) 874 (88)
Black/Mulatto 32 (10) 40 (12) 40 (12) 112 (11)
Asian 3 ( 1) 4 ( 1) 2 ( 1) 9 ( 1)
CD4 cell count stratum - no. (%)
50 to 150 cells/mm3 153 (46) 150 (45) 158 (48) 461 (46)
151 to 250 cells/mm3 179 (54) 182 (55) 174 (52) 535 (54)
HIV infection risk factors† - no. (%)
Homosexual/bisexual sexual contact 123 (37) 125 (38) 134 (40) 382 (38)
Heterosexual Sexual contact 139 (42) 140 (42) 136 (41) 415 (42)
Intravenous drug abuse 52 (16) 40 (12) 37 (11) 129 (13)
Hemophilia/blood transfusion 6 ( 2) 6 ( 2) 2 ( 1) 14 ( 1)
Not known 23 ( 7) 26 ( 8) 30 ( 9) 79 ( 8)
Median CD4 cell count
(Q1-Q3; cells/mm3) 146 (86, 207) 147 (99, 194) 148 (91, 201) 147 (91, 202)
Median HIV RNA
(Q1-Q3; log10 copies/mL)‡ 4.56 (4.13, 4.93) 4.38 (3.94, 4.75) 4.56 (4.12, 4.93) 4.49 (4.07, 4.91)
* Includes 2 patients of Hispanic origin (1 in the indinavir treatment group, and 1 in the zidovudine treatment group).
† Patients could have multiple risk factors.
‡ Values that were below the assay threshold of quantification (<500 copies/mL) were coded as equal to 500 copies/mL (2.70 log10 copies/mL).
Nonamplifiable results (those below the assay threshold of detection) were reported as “negative” by the laboratory, but, for purposes of data
analysis, these results were coded as equal to 250 copies/mL (2.40 log10 copies/mL).
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Fig. 1 - Kaplan-Meier estimates of the proportions of patients not reaching the primary study end point of progression to AIDS event or death.
The comparison of indinavir plus zidovudine versus indinavir was not
statistically significant (p=0.2863, stratified log rank test) with an
estimated hazard ratio of 0.77 (95% confidence interval: 0.72, 2.32).
The percentage reductions in hazard for the indinavir plus zidovudine
and indinavir groups compared to the zidovudine group were 70% and
61%, respectively.
Mortality
A total of 25 (2%) of the 996 patients enrolled died: 8 (3%) from the
indinavir plus zidovudine treatment group, 5 (2%) from the indinavir
group, and 12 (4%) from the zidovudine group. None of the between-
treatment comparisons was statistically significant by the stratified log
rank test.
Surrogate Marker Efficacy Follow-Up Period
The median follow-up available for the two measures of surrogate
marker efficacy (HIV RNA, CD4) differed because different laboratories
and data handling procedures were utilized for CD4 cell counts and HIV
RNA measurement. The median follow-up for HIV RNA was 68 weeks
(range 0 to 104 weeks) for all 984 patients with baseline and at least one
post-randomization HIV RNA measurement. The median follow-up for
CD4 cell counts was 48 weeks (range 0 to 96 weeks) for all 996 patients
enrolled. For both HIV RNA and CD4 cell counts, a change in trajectory
was seen after Week 48 in the zidovudine-containing groups.
Changes in Viral RNA
The adjusted mean change in HIV RNA over available follow-up, as
measured by the AUCMB, was statistically significantly greater (p<0.0001)
for the indinavir plus zidovudine group (-1.04 log10 copies/mL) than for
the zidovudine group (-0.28 log10 copies/mL). Likewise, the adjusted mean
change in HIV RNA for the indinavir group (-0.68 log10 copies/mL) was
statistically significantly greater than the change for the zidovudine group
(p<0.0001). The difference between the indinavir plus zidovudine and
indinavir groups was statistically significant (p<0.0001). At the median
follow-up of 68 weeks, 37% of patients on indinavir plus zidovudine,
23% of patients on indinavir, and 6% of patients on zidovudine had HIV
RNA levels below 500 copies/mL.
Changes in CD4 Cell Counts
Figure 2 displays observed mean changes in CD4 cell counts by
treatment group. The adjusted mean change in CD4 cell count over
available follow-up, as measured by the AUCMB, was statistically
significantly greater (p<0.0001) for the indinavir plus zidovudine group
(109.7 cells per cubic millimeter) than for the zidovudine group (20.1
cells per cubic millimeter). Likewise, the adjusted mean change in CD4
cell count for the indinavir group (93.6 cells per cubic millimeter) was
statistically significantly greater than the change for the zidovudine group
(p<0.0001). The difference between the indinavir plus zidovudine and
indinavir groups was not statistically significant (p=0.2552).
 Association Between Surrogate Markers and Progression of
Disease
The subgroup of patients with data for both CD4 cell count and HIV
RNA at study entry and at least one post-randomization result included
967 patients (97% of total enrollment). There were 107 patients in this
subgroup with at least one clinical event.
Low risk of progression was defined primarily by CD4 cell count.
The majority of clinical events occurred in patients enrolled into the
lower CD4 stratum (50-150 cells/mm3). The last available CD4 cell count
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Fig. 2 - Mean (95% CI) change from baseline in CD4 cell counts (cells/mm3) by treatment group.
Fig. 3 - Kaplan-Meier estimates of proportions of patients with progression-free survival by viral suppression status (HIV RNA
nadir below threshold of quantification versus HIV RNA nadir above 500 copies/mL).
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was associated with clinical benefit; patients with low CD4 cell counts
had the highest risk of disease progression.
Patients who had at least one HIV RNA result below 500 copies/mL
had markedly reduced risk of disease progression relative to those whose
HIV RNA never was below this threshold (88% risk reduction for all
treatments pooled, p<.0001, Figure 3). This analysis included all patients
who achieved HIV RNA suppression to below 500 copies/mL at any
time during the study regardless of treatment group, including 196/
319 (61%) of the patients who were randomized to receive indinavir
plus zidovudine, 169/323 (52%) of the patients randomized to receive
indinavir and 52/325 (16%) of the patients randomized to receive
zidovudine. The majority of patients (95%) who had at least one HIV
RNA measurement below 500 copies/mL also had at least 2 consecutive
measurements showing this degree of HIV RNA suppression. While for
all three treatment groups, having HIV RNA nadirs below 500 copies/
mL was associated with reduced clinical progression risk, the magnitude
of this association was greater for the indinavir containing arms than in
the control arm.
However, improvement in both CD4 cell count and HIV RNA are
associated with reduced risk of disease progression. Patients were divided
into quartiles based on average changes in CD4 cell count and HIV
RNA (Figure 4). The patients with increases in CD4 cell count as well
as decreases in HIV RNA had a statistically significant increase in
progression-free survival compared to the patients in the other three
quadrants (p<0.006).
Safety
The proportion of patients with clinical adverse experiences was
similar in all treatment groups. The most common clinical adverse
experiences were: abdominal pain, fever, asthenia/fatigue, and malaise.
The incidence of nephrolithiasis attributable to indinavir was
approximately 8%. The proportions of patients with nephrolithiasis were
12% (40/332) in the indinavir plus zidovudine group, 12% (40/332) in
the indinavir group and 4% (13/332) in the zidovudine group. Overall,
122 (12%) patients had serious adverse experiences during the trial: 36
(11%) in the indinavir plus zidovudine group, 33 (10%) in the indinavir
group and 53 (16%) in the zidovudine group. Many of the serious adverse
events were clinical events or adverse experiences associated with clinical
events.
Twenty-nine (2.9%) of 996 patients permanently discontinued some
or all of their study therapy due to clinical or laboratory adverse
experiences prior to a clinical event. The proportion of patients in the
indinavir arm (3/332, 0.9%) who discontinued therapy due to adverse
experiences was statistically significantly less (p=0.0099, Fishers exact
test) than in either the indinavir plus zidovudine arm (13/332, 4%) or
the zidovudine arm (13/332, 4%). The proportions of patients who
discontinued study therapy in the two zidovudine containing arms were
not statistically significantly different.
Five (0.5%) of 996 patients discontinued study due to clinical or
laboratory adverse experiences: 2/332 (0.6%) in the indinavir plus
zidovudine group (due to headache/nausea/vomiting, and exanthema),
Fig. 4 - Kaplan-Meier estimates of the proportions of patients not reaching the primary study end point of progression to AIDS
event or death - by surrogate marker AUCMB quadrants.
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1/332 (0.3%) in the indinavir group (due to extrapulmonary
cryptococcosis) and 2/332 (0.3%) in the zidovudine group (due to
decreased neutrophils, and nausea/vomiting).
Laboratory results were evaluated using the AIDS Clinical Trials
Group Grade 3 definitions for severity9. The proportions of patients with
hyperbilirubinemia (>2.5 mg/dL) was statistically significantly higher
in the indinavir containing groups than in the zidovudine group
(p<0.0001, Fishers exact test). The proportions of patients with
hematologic abnormalities (decreased hemoglobin [<7 g/dL], decreased
absolute neutrophil count [<750 ths/mm3]) were statistically significantly
higher in the zidovudine group than in the indinavir group (p=0.0061
and p=0.0046, respectively). Hyperglycemia (>250 mg/dL) occurred in
1.2% (4/321), 0.9% (3/329), and 0.6% (2/330) of patients in the indinavir
plus zidovudine, indinavir, and zidovudine groups, respectively.
Hypertriglyceridemia (>750 mg/dL) occurred in 3.1% (10/321), 3.0%
(10/329), and 4.2% (14/330) of patients in the indinavir plus zidovudine,
indinavir, and zidovudine groups, respectively. There were no statistically
significant differences between treatment groups with respect to
hyperglycemia (p=0.590) and hypertriglyceridemia (p=0.690).
DISCUSSION
This study demonstrates the considerable antiretroviral effect of
indinavir, alone and in combination with zidovudine, compared to
zidovudine alone in HIV-1 seropositive treatment-naive patients with
average CD4 cell counts of 50 to 250 cells/mm3, with respect to
progression to an AIDS-defining event or death. In addition, consistent
benefit was demonstrated with respect to changes from baseline in CD4
cell counts and HIV RNA.
The percent reductions in hazards for the indinavir plus zidovudine
and indinavir groups compared to the zidovudine group were 70% and
61%, respectively. Both indinavir groups were statistically significantly
different from zidovudine but not from each other. The overall occurrence
of events was similar to available epidemiologic data regarding the
occurrence of AIDS-defining events in the state of São Paulo, Brazil29.
The indinavir-treated patients had sustained increases in CD4 cell
count during the study. The average changes from baseline in CD4 cell
count in the indinavir-containing groups were statistically significantly
greater than for the zidovudine group, but the indinavir groups were not
statistically different from each other. At Week 48, the median elevation
in CD4 cell count was >100 cells/mm3 above baseline in both indinavir-
containing groups.
In analyzing the changes in CD4 cell counts and HIV RNA, a change
in trajectory was observed after Week 48 in the indinavir plus zidovudine
and zidovudine groups. This change may be due to the addition of
lamivudine, or due to censoring of surrogate marker follow-up after
experiencing a DSMB-confirmed clinical event. The median study time
for addition of lamivudine or placebo to lamivudine was Week 41.
A large proportion of indinavir-treated patients had sustained
decreases in HIV RNA to <500 copies/mL, which represents the lower
limit of quantification of the assay. Recently the proportion of patients
achieving maximal HIV RNA suppression has become the standard for
evaluating antiretroviral therapies1,3. The indinavir plus zidovudine group
had a greater and more sustained suppression of HIV RNA compared to
the other groups as measured by proportions of patients with HIV RNA
<500 copies/mL or changes from baseline HIV RNA. Over the duration
of the study, the indinavir group had greater HIV RNA suppression than
the zidovudine group. However, at later timepoints the change from
baseline for HIV RNA is similar between the indinavir and zidovudine
groups.
This study provides further confirmation of the clinical benefit of
protease inhibitors in treating HIV-infected patients2,14,25,27. The study
also provides information on the relationship between changes in CD4
cell counts and HIV RNA and disease progression. The indinavir
containing groups both had decreased disease progression compared to
the zidovudine control group. The indinavir containing groups showed
similar benefit with regard to change from baseline in CD4 cell counts
but indinavir plus zidovudine treatment resulted in a statistically
significantly greater decline in HIV RNA when compared to indinavir
alone. The difference between the HIV RNA suppression in the two
indinavir-containing groups appeared to be greater at later timepoints
although this observation is complicated by the addition of lamivudine
to the indinavir plus zidovudine group. However, suppression of HIV
RNA to below 500 copies/mL was clearly associated with a decreased
risk of disease progression, supporting the prognostic value of HIV RNA
quantification demonstrated previously5,15,17,20,22,24,26,32. Although the study
demonstrates clinical benefit from indinavir alone or in combination
with zidovudine, recent data suggest that using indinavir in combination
with other antiretroviral agents (zidovudine plus lamivudine, stavudine
plus didanosine, stavudine plus lamivudine, efavirenz) results in greater
and more durable antiviral activity which will likely result in greater
longterm clinical benefit10,11,14,16,30.
Overall, 14% of patients discontinued from the study without
experiencing a DSMB-confirmed clinical event. In the indinavir plus
zidovudine group, 17% of patients discontinued, as compared to 11%
of patients in the indinavir arm, and 13% in the zidovudine arm. The
highest discontinuation rate occurred in the group with the numerically
superior surrogate marker responses. This was of concern because the
potential differential loss of patients who were not doing well from a
specific treatment group might bias the final study results. Therefore,
attempts were made to obtain a follow-up status on those patients who
discontinued from the study. Ultimately, survival and progression
information was available for 95% of all patients enrolled. Analyses
including this additional follow-up information indicated that patient
discontinuations did not affect the primary study conclusions.
This study clearly demonstrates the marked clinical efficacy and
general tolerability of indinavir, either alone or in combination with
zidovudine, in treatment-naive HIV-infected patients with moderate
degrees of immunosuppression. Although the study was initiated prior
to the demonstration of the potency of combination therapy, the study
was amended to reflect the current standard of care. Profound and durable
improvements in CD4 cell counts and viral load were also demonstrated.
Because of the large sample size and the long follow-up, this study allows
a unique opportunity to explore associations between surrogate marker
changes and clinical outcome. This study shows that the combination of
favorable CD4 cell count and HIV RNA changes are associated with a
decrease in the risk of HIV disease progression. At a time when advances
in the treatment of HIV infection and the prevention of opportunistic
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infections have complicated the conduct of clinical endpoint trials, the
results of this study support the utility of long-term surrogate marker
responses in assessing antiretroviral treatment regimens.
RESUMO
Estudo duplo-cego, randômico comparando indinavir, zidovudina
e indinavir mais zidovudina na terapia anti-retroviral de
indivíduos HIV+ sem tratamento anterior, com contagem de
células CD4 entre 50 e 250/mm3
Foi demonstrado que o tratamento com indinavir resulta em
importante redução da carga viral e aumentos das células CD4 em
pacientes infectados pelo HIV. Foi realizado um estudo duplo-cego,
randômico para avaliar a eficácia do indinavir isoladamente (800 mg
cada 8h), zidovudina isoladamente (200 mg cada 8h) ou a combinação,
para avaliar a progressão para AIDS. Foram distribuidos para tratamento
996 pacientes virgens de tratamento antiretroviral, com contagens de
CD4 entre 50 e 250 células/mm3. Durante o estudo, o protocolo foi
modificado para adicionar lamivudina aos braços contendo zidovudina.
O “endpoint” primário foi o tempo para o desenvolvimento de uma
doença-definidora de AIDS ou morte. O estudo foi interrompido após
uma análise preliminar definida no protocolo ter demonstrado reduções
significativas na progressão para um evento clínico nos grupos contendo
indinavir, comparado ao grupo da zidovudina (p< 0,0001). Após uma
mediana de seguimento de 52 semanas (chegando a 99 semanas), as
reduções percentuais nas ocorrências para indinavir+zidovudina e
indinavir, comparado com zidovudina foram de 70% e 61%, respecti-
vamente. Reduções significativas na medida do RNA viral e aumentos
nas contagens de CD4 também foram observadas nos grupos contendo
indinavir, em relação ao da zidovudina. A melhora nas células CD4 e
RNA viral foram ambas associadas a risco reduzido de progressão da
doença. Os três tratamentos foram geralmente bem tolerados.
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